After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

The world’s deadliest infectious disease urgently requires new and effective antibiotics. Researchers have created a promising new compound that may mark a major step forward in the global effort to ...

The U.S. Food and Drug Administration has placed a clinical hold on Intellia Therapeutics' two late-stage trials testing an ...

Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet ...

Blocking caspase-9, an enzyme involved in cell death, may be a potential treatment target for pulmonary fibrosis, a ...

In early 2022, Connor started a new medication called Nexviazyme, but each treatment took 13 hours. This summer, he received ...

First and only disease-modifying therapy for the treatment of eligible children with MLD also receives Orphan Drug Designation and Priority Review in the Kingdom of Saudi Arabia - ...

Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

Archer-Daniels-Midland Company (($ADM)) announced an update on their ongoing clinical study. Archer-Daniels-Midland Company ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

Two officials are suspended following an incident where five children received HIV-positive blood. The Jharkhand Chief ...

In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...